Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Retained Earnings (2016 - 2025)

Tg Therapeutics (TGTX) has 10 years of Retained Earnings data on record, last reported at -$1.1 billion in Q4 2025.

  • For Q4 2025, Retained Earnings rose 28.07% year-over-year to -$1.1 billion; the TTM value through Dec 2025 reached -$1.1 billion, up 28.07%, while the annual FY2025 figure was -$1.1 billion, 28.07% up from the prior year.
  • Retained Earnings reached -$1.1 billion in Q4 2025 per TGTX's latest filing, roughly flat from -$1.1 billion in the prior quarter.
  • Across five years, Retained Earnings topped out at -$1.1 billion in Q1 2021 and bottomed at -$1.6 billion in Q2 2023.
  • Average Retained Earnings over 5 years is -$1.4 billion, with a median of -$1.5 billion recorded in 2022.
  • Peak YoY movement for Retained Earnings: plummeted 42.39% in 2021, then surged 30.93% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$1.3 billion in 2021, then decreased by 12.89% to -$1.5 billion in 2022, then fell by 3.51% to -$1.6 billion in 2023, then rose by 1.51% to -$1.5 billion in 2024, then rose by 28.07% to -$1.1 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were -$1.1 billion in Q4 2025, -$1.1 billion in Q3 2025, and -$1.5 billion in Q2 2025.